SG11202112513YA - Methods of administering anti-cd38 antibody to treat multiple myeloma - Google Patents

Methods of administering anti-cd38 antibody to treat multiple myeloma

Info

Publication number
SG11202112513YA
SG11202112513YA SG11202112513YA SG11202112513YA SG11202112513YA SG 11202112513Y A SG11202112513Y A SG 11202112513YA SG 11202112513Y A SG11202112513Y A SG 11202112513YA SG 11202112513Y A SG11202112513Y A SG 11202112513YA SG 11202112513Y A SG11202112513Y A SG 11202112513YA
Authority
SG
Singapore
Prior art keywords
antibody
methods
multiple myeloma
treat multiple
administering anti
Prior art date
Application number
SG11202112513YA
Other languages
English (en)
Inventor
Heloise Audat
Sylvia Marion
Zambrano Frank Campana
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202112513YA publication Critical patent/SG11202112513YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202112513YA 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma SG11202112513YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US201962899088P 2019-09-11 2019-09-11
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Publications (1)

Publication Number Publication Date
SG11202112513YA true SG11202112513YA (en) 2021-12-30

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112513YA SG11202112513YA (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Country Status (15)

Country Link
US (1) US20210171650A1 (ko)
EP (1) EP3969004A1 (ko)
JP (1) JP2022532356A (ko)
KR (1) KR20220008305A (ko)
CN (1) CN114080233A (ko)
AU (1) AU2020274169A1 (ko)
BR (1) BR112021022503A2 (ko)
CA (1) CA3140034A1 (ko)
CO (1) CO2021016606A2 (ko)
IL (1) IL287832A (ko)
MA (1) MA55967A (ko)
MX (1) MX2021013910A (ko)
SG (1) SG11202112513YA (ko)
TW (1) TW202108624A (ko)
WO (1) WO2020232173A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3197381A1 (en) * 2020-11-03 2022-05-12 Sanofi-Aventis U.S. Llc Use of isatuximab for the treatment of multiple myeloma
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3917961A1 (en) * 2019-01-28 2021-12-08 Sanofi Methods of treating multiple myeloma

Also Published As

Publication number Publication date
TW202108624A (zh) 2021-03-01
MA55967A (fr) 2022-03-23
EP3969004A1 (en) 2022-03-23
AU2020274169A1 (en) 2022-01-20
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (en) 2020-11-19
CN114080233A (zh) 2022-02-22
MX2021013910A (es) 2022-03-11
IL287832A (en) 2022-01-01
KR20220008305A (ko) 2022-01-20
WO2020232173A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
BR112021022503A2 (pt) 2021-12-28
JP2022532356A (ja) 2022-07-14

Similar Documents

Publication Publication Date Title
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
IL288523A (en) Compounds for the treatment of pd-l1 diseases
EP3244926A4 (en) Treatment of cancer with anti-lap monoclonal antibodies
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
EP3866794A4 (en) METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE COMPOUNDS
PH12014501338A1 (en) Chimeric therapeutic anti-cd37 antibodie hh1
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
IL275321A (en) Treatment of diseases associated with the expression of DUX4
IL287832A (en) Methods for administering anti-cd38 antibody for the treatment of multiple myeloma
MX348311B (es) Inhibidores nampt.
HK1249016A1 (zh) 使用抗il-34抗體治療神經疾病的組合物和方法
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
IL285110A (en) Methods for treating multiple myeloma
IL252535A0 (en) A combination of cs1 and pd1 antibodies for the treatment of cancer (myeloma)
EP3645042A4 (en) HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND THEIR MANUFACTURING AND USE METHODS
IL271488A (en) Chimeric antibodies for the treatment of diseases characterized by amyloid deposition
IL290111A (en) Methods for administration of anti-siglec-8 antibodies and corticosteroids
EP3092002A4 (en) Method of purifying monoclonal antibodies
MX2017011272A (es) Metodo de tratamiento para la colangitis esclerosante primaria.
MX2017014396A (es) Tratamiento de mieloma multiple.
EP3440225A4 (en) THERAPEUTIC ANTIBODIES FOR TREATING NEURODEGENERATION
IL287759A (en) Treatment of headaches using anti-cgrp antibodies
IL287179A (en) Bryostatin compounds to improve immunotherapy